Health Care Select Sector SPDR Fund
0
Funds holding %
of 7,296 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
24% more first-time investments, than exits
New positions opened: 161 | Existing positions closed: 130
12% more funds holding in top 10
Funds holding in top 10: 84 [Q4 2024] → 94 (+10) [Q1 2025]
0.99% more ownership
Funds ownership: 71.58% [Q4 2024] → 72.57% (+0.99%) [Q1 2025]
0% less funds holding
Funds holding: 1,738 [Q4 2024] → 1,730 (-8) [Q1 2025]
1% less repeat investments, than reductions
Existing positions increased: 657 | Existing positions reduced: 664
2% less capital invested
Capital invested by funds: $28.3B [Q4 2024] → $27.9B (-$464M) [Q1 2025]
44% less call options, than puts
Call options by funds: $1.68B | Put options by funds: $3.01B
Research analyst outlook
We haven’t received any recent analyst ratings for XLV.
Financial journalist opinion
Based on 10 articles about XLV published over the past 30 days
Negative
CNBC Television
2 days ago
I've never seen a setup this negative for health care job growth, says Bancreek's Pachman
CNBC's “Power Lunch” is joined by Eric Pachman, chief analytics officer at Bancreek Capital Advisors, to discuss the U.S. labor market, whether health care jobs are in jeopardy and more.
Neutral
Zacks Investment Research
4 days ago
Should You Invest in the Health Care Select Sector SPDR ETF (XLV)?
The Health Care Select Sector SPDR ETF (XLV) was launched on 12/16/1998, and is a passively managed exchange traded fund designed to offer broad exposure to the Healthcare - Broad segment of the equity market.
Positive
Market Watch
1 week ago
Healthcare companies are hiring. Is it time to look for growth stocks in this beaten-down sector?
The recent jobs data showed that hiring in healthcare took a big jump in May, as the stock sector has stabilized a bit after years of underperformance.
Neutral
Zacks Investment Research
1 week ago
6 ETFs to Invest in June
The S&P 500 roared to its best May in over 30 years, what???s next for June?
Positive
CNBC Television
1 week ago
Buy America, says John Hancock's Matthew Miskin
Matthew Miskin, John Hancock Investment Management, joins 'The Exchange' to discuss markets, small and mid-caps and the industrial sector.
Positive
Yahoo Finance
1 week ago
How pet medicine stocks could cushion your healthcare investments from Trump changes
Moderna shares are seeing a boost on Monday after the US Food and Drug Administration (FDA) gave the pharmaceutical giant limited approval for its lower-dose COVID-19 vaccine. Morgan Stanley Investment Management portfolio manager Jason Kritzer shares his perspective on the pharmaceutical industry amid pushback from the Trump administration's Department of Health and Human Services (HHS) Secretary Robert F.
Negative
Seeking Alpha
1 week ago
The HealthCare Sector: A Look At Sector Earnings Trends
Looking at Q1 '25 earnings trends, the healthcare sector reported a solid quarter, even with UnitedHealth's issues. Q2 and Q3 '25 are showing lower or negative revisions, and lower levels of absolute healthcare EPS growth. It looks like Q2 '25 could be the low point for healthcare sector earnings growth for this year, but the sector is being buffeted by a number of headwinds.
Positive
Seeking Alpha
2 weeks ago
3 Deep-Value Blue Chips: The Fat Pitch I Couldn't Resist
The worst-case scenario of big global tariffs and a severe recession is now off the table, lowering risk and supporting a new bull market. UnitedHealth offers a Buffett-style deep value opportunity after a 50% drop, with long-term growth and credit quality intact. UNH's historical growth rate of 14% to 15% is expected to continue after 2025, which results in a 240% return potential (25% CAGR) over five years.
Neutral
Seeking Alpha
2 weeks ago
Healthcare Sector Checkup As U.S. Looks To Change Regulations
Outlook for pharma sector as Trump pushes for regulatory changes. The impact of tariffs on drugmakers.
Positive
CNBC Television
2 weeks ago
Jefferies' Michael Yee: Drug discovery could be one of the biggest beneficiaries of generative AI
Michael Yee, Jefferies senior biotech analyst, joins CNBC's 'Squawk on the Street' to discuss how AI could fuel drug discovery and development, the timeline for when pharmaceutical companies could see benefits from AI, and more.
Charts implemented using Lightweight Charts™